SOPHIA ANTIPOLIS, France – July 11, 2025 │ KnowMade actively tracks therapeutic mRNA innovations as part of its Therapeutic mRNA patent monitoring service. What’s new today? Emerging Innovators in a Record-Setting Quarter for Therapeutic mRNA The continued innovation in therapeutic mRNA is confirmed through the first half of 2025, as reflected by KnowMade’s Therapeutic mRNA[…]
SOPHIA ANTIPOLIS, France – July 10, 2025 │ In July, Regeneron received accelerated approval from the FDA for its bispecific antibody (bsAb) Linvoseltamab (brand name Lynozyfic). It is intended to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least 4 prior lines of therapy, including a proteasome inhibitor,[…]
SOPHIA ANTIPOLIS, France – May 30, 2025 │ CytomX Therapeutics announced positive Phase 1 data for its Epithelial Cell Adhesion Molecule (EpCAM) PROBODY® Antibody Drug Conjugate candidate, CX-2051, in advanced Colorectal Cancer (CRC). CytomX Therapeutics: precision oncology through Probody® innovation CytomX Therapeutics is based in South San Francisco, California. It was founded in 2008 by[…]
SOPHIA ANTIPOLIS, France – April 11th, 2025 │ On March 19th, 2025, a collaboration was announced between Oxford BioTherapeutics (OBT) and Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer. Targets will be identified via the OGAP®-Verify discovery platform of OBT, a proprietary database on membrane protein abundance, with around 7,000[…]